Formulation and Evaluation of Mouth Dissolving Film of Prochlorperazine Maleate

Rajat Pawar1, Ravi Sharma1, Gajanan Darwhekar1
Acropolis Institute of Pharmaceutical Education and Research, Indore, India

ABSTRACT

This research work aimed to enhance the oral bioavailability and provide faster onset of action of Prochlorperazine maleate (used for the treatment of nausea and vomiting) by formulating its mouth dissolving film (MDF). Prochlorperazine belongs to BCS II and oral bioavailability of it’s about 11–15%. The MDF of Prochlorperazine maleate was prepared by solvent casting method using HPMC (film forming agent), Glycerol (plasticizer), Betacyclodextrin (solubilizing agent), Citric acid (saliva stimulating agent), Mannitol (sweetening agent). The formulation was optimized by two factors, three levels [3] was used for the formulation optimization of fast dissolving film of Prochlorperazine maleate and experimental trials are performed on all 9 formulations. In which the amount of HPMC, Glycerol were selected as independent variables (factor) varied at three different level: low (-1), medium (0), and high (+1) levels. The drug release and disintegration time used as dependent variables (response), and formulation was evaluated for weight variation, thickness, folding endurance, drug content, in-vitro disintegration, in-vitro dissolution study and stability study. Based on results it was concluded that MDF (F3) showed enhanced bioavailability and faster onset of action.

Keywords: Prochlorperazine maleate, Mouth dissolving film, bioavailability

INTRODUCTION

The oral route is one of the most favoured routes of drug administration about 60% of all the formulations are solid dosage form. Tablet is the most preferred dosage form due to ease of transportation, as it is more suitable, cost effective, and ease of administration leads to high degree of patient compliance. However, peroral administration of drugs has demerits like liver degradation and enzymatic degradation within the gastrointestinal tract, that diallow oral administration of various types of drugs especially peptides and proteins. Within the oral mucosal cavity, the buccal area seems to be one of the preferred routes for delivery of drug systemically. It provides benefits like prevention of hepatic first pass metabolism within the gastrointestinal tract, also provides improved enzyme flora for absorption of drugs [1].

Fast dissolving drug delivery system was developed in 1970s to beat swallowing problems linked with tablets and capsules for children and elderly sufferers. Oral mucosal drug delivery is vital route of drug administration. Several bioadhesive oral mucosal dosage forms have been invented, which includes mucoadhesive tablets, gels, ointments, patches, and the use of films for buccal delivery, also known as oral thin strips [4].

Buccal cavity is made up of stratified squamous epithelium i.e. separated from the lamina propria and sub mucosa. The penetrability of buccal mucosa is 4–4,000 times larger than the skin, and is less than that of the intestine. Therefore, the buccal delivery is an outstanding platform for absorption of molecules with poor skin penetration [2]. The prime obstacle to permeability in oral mucosa is the outcome of intercellular objects generated from the ‘membrane covering granules’ which is present at the topmost 200 μm layer. These oral film strips have a shelf life of 2-3 years, based on the active pharmaceutical ingredient but are tremendously responsive to environment humidity [4].

MATERIAL AND METHODS

Materials:
Prochlorperazine maleate was obtained as Yarrow chem. pvt. Ltd. HPMC, Glycerol, Betacyclodextrin, Mannitol, Citric acid was obtained from loba chemicals.

Methods:

Preformulation Study

Identification of Drug:

When the drug Prochlorperazine maleate was examined in the range 220 nm to 360 nm, the 0.001% w/v solution in ethanol (95 percent) containing 0.01 percent v/v of strong ammonia Solution shows an absorption maximum at 255 nm [3].
Determination of Melting Point:
Melting point of drug sample was determined by using melting point apparatus. Drug sample was taken and placed in a thin walled capillary tube; the tube was approximately 10-12 cm in length with 1mm in diameter and closed at one end. The capillary was placed in melting point apparatus and gradually temperature rises when drug sample was melted the melting point of sample powder was recorded.

Determination of solubility:
Preparation of calibration curve of Prochlorperazine maleate:
The calibration curves of Prochlorperazine maleate were prepared in distilled water and phosphate buffer pH 6.8 by using Shimadzu 1800 UV visible spectrophotometer. Accurately weighed 50 mg of Prochlorperazine maleate was transferred into a 50 ml volumetric flask and the volume was made up by using co solvent with distilled water to obtain a 1000μg/ml stock solution of Prochlorperazine maleate. From the stock solution 1 ml was taken and transferred into a 10 ml volumetric flask and rest of the volume was made up with solvent to obtain a 100μg/ml of solution from which further dilutions of 5, 10,15,20,25 μg/ml were prepared. Same procedure was followed for phosphate buffer pH 6.8 to prepare calibration curve.

Determination of solubility of Prochlorperazine maleate in various medium:
The solubility of Prochlorperazine maleate in various medium was determined by equilibrium solubility method. In this method 5 ml of each solvent was taken into a separate vial and excess amount of Prochlorperazine maleate was added in to vials containing distilled water and phosphate buffer pH 6.8. The vials put on magnetic stirrer for 12 hrs. The solution was allowed to equilibrate for next 24 h. The solution was transferred into eppendorf tubes and centrifuged for 5 min. at 2000 rpm. The supernatants of each vial were filter through 0.45micron membrane filter, make appropriate dilutions and analyzed by UV visible spectrophotometer (UV-1800 Shimadzu, Japan ) at 255 nm, the studies was performed in triplicate.

Formulation of MDFs of Prochlorperazine maleate
Mouth dissolving films were prepared by solvent casting method as per the composition shown in table 1.

Table 1. Formulation optimization of Mouth dissolving film

| BATCH NO. | INGREDIENTS                  | F1  | F2  | F3  | F4  | F5  | F6  | F7  | F8  | F9  |
|-----------|------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|           | Drug+Betacyclodextrin solid dispersion | 40  | 40  | 40  | 40  | 40  | 40  | 40  | 40  | 40  |
|           | HPMC (mg)                    | 500 | 500 | 500 | 350 | 350 | 350 | 250 | 250 | 250 |
|           | Glycerol (ml)                | 0.05| 0.1 | 0.075| 0.05| 0.1 | 0.075| 0.05| 0.1 | 0.075|
|           | Citric acid (mg)             | 20  | 20  | 20  | 20  | 20  | 20  | 20  | 20  | 20  |
|           | Mannitol (mg)                | 20  | 20  | 20  | 20  | 20  | 20  | 20  | 20  | 20  |
|           | Distilled water (ml)         | 10  | 10  | 10  | 10  | 10  | 10  | 10  | 10  | 10  |

Evaluation of Mouth dissolving films:

Weight of films:
9 films were weighed on analytical balance and average weight was determined for each film. It is desirable that films should have nearly constant weight. It is useful to ensure that a film contains the proper amount of excipients and API[7]

Film thickness:
The thickness of the film was measured by micrometer screw gauge (Aculab) at three different places; averages of three values were calculated. This is essential to ascertain uniformity in the thickness of the film this is directly related to the accuracy of dose in the film[8]

Folding endurance:
The folding endurance is expressed as the number of folds (number of times the film is folded at the same place, either to break the specimen or to develop visible cracks). This test is important to check the ability of the sample to withstand folding. This also gives an indication of brittleness. The folding endurance of the strips was determined by repeatedly folding one film at the same place till it broke.[8]

Drug Content Uniformity:
Drug content was determined by dissolving the prepared mouth dissolving film (MDF) of prochlorperazine maleate drug in 100 ml of phosphate buffer pH 6.8. The aliquot of 1ml was taken and diluted to 10ml with distilled water.
Then solution was filtered through whatman filter paper and solution was analyzed on UV spectrophotometer at desired wavelength to calculate the amount of drug present in the film.

**In-vitro disintegration test:**

The in vitro disintegration study of the mouth dissolving film was carried out using 10 ml of water at 36°C and it was placed in a petridish of 10 cm diameter. Each MDF was carefully kept at the centre of the petridish and the time required for the MDF to completely disintegrate was noted.

**In-vitro Dissolution test:**

The dissolution study of the Mouth dissolving film was determined in Electrolab Dissolution Apparatus type II following USP Paddle method. All tests were conducted in 900 ml of Phosphate buffer pH 6.8. The dissolution medium was maintained at 37±0.5°C and paddle rotation speed at 50 rpm. Allquot of 5ml was withdrawn at specific intervals and were immediately filtered through Whatman filter paper and analyzed spectrophotometrically. The absorbance values were transformed to concentration by reference to a standard calibration curve obtained experimentally measured on UV spectrophotometer.

**Stability Studies**

Stability studies were conducted on prepared films to assess their stability with respect to their physical appearance, drug content and drug release characteristics after storing them at 40°C /65 % RH for 2 months. Samples were withdrawn at 0, 30, and 60 days.

**RESULT AND DISCUSSION**

**Identification of drug:**

The UV spectrum of Prochlorperazine maleate shows prominent absorbance maxima at wavelength 255 nm (fig No. 1.1) which is similar to the standard peaks therefore confirmed the identity of sample drug as Prochlorperazine maleate. Reported absorbance maxima were Prochlorperazine maleate were λmax at 255nm.

**Preparation of calibration curves:** The calibration curves of Prochlorperazine maleate in various solvents e.g. Distilled water, 6.8 pH phosphate buffers were prepared.

**Table 2. Absorbance data of Prochlorperazine maleate in distilled water for preparation of calibration curve, at 255nm**

| S. No. | Concentration (µg/ml) | Absorbance |
|--------|-----------------------|------------|
| 1      | 5                     | 0.233      |
| 2      | 10                    | 0.454      |
| 3      | 15                    | 0.666      |
| 4      | 20                    | 0.902      |
| 5      | 25                    | 1.062      |

**Calibration curve of Prochlorperazine maleate in Distilled water**

Calibration curve of Prochlorperazine maleate in distilled water 255.0nm
Table 3. Absorbance data of Prochlorperazine maleate in phosphate buffer pH 6.8 for preparation of calibration curve, at 255 nm.

| S. No. | Concentration (µg/ml) | Absorbance |
|--------|-----------------------|------------|
| 1      | 5                     | 0.220      |
| 2      | 10                    | 0.457      |
| 3      | 15                    | 0.762      |
| 4      | 20                    | 1.055      |
| 5      | 25                    | 1.247      |

Calibration curve of Prochlorperazine maleate in pH 6.8 255.0nm

Determination of solubility of Prochlorperazine maleate in various medium:
The solubility of Prochlorperazine maleate in various medium was studied and the results of study were shown in below table.

Table 4. Solubility data of Prochlorperazine maleate different mediums

| S.No. | Solvent                        | Solubility (mg/ml) Mean±SD |
|-------|--------------------------------|----------------------------|
| 1     | Distilled water                | 0.0138±0.03                |
| 2     | Phosphate buffer pH 6.8        | 1.152±0.00                 |

Determination of solubility of Solid Dispersion:
The solubility of inclusion complex in phosphate buffer pH 6.8 and distill water was studied and the results of study were shown in below table.

Table 5. Solubility data of solid Dispersion:

| S.No. | Solvent                        | Solubility (mg/ml) Mean±SD |
|-------|--------------------------------|----------------------------|
| 1     | Distilled water Drug:β-CD (1:3)| 1.135±0.00                 |
| 2     | Phosphate buffer pH 6.8 Drug:β-CD (1:3)| 13.195±0.87          |

Drug-excipient interaction study: The drug (Prochlorperazine maleate) was found to be compatible with various excipients which were selected for formulation of fast dissolving film. The compatibility was assessed by TLC and the retention factors of all ratios found similar.
Table 6: Data of drug-excipient interaction study:

| S.No. | Drug/ drug+ Excipient Ratio (1:1) | Physical appearance (initial) | Present Day (Rf) | Physical appearance (final) | After15 Days (Rf) | Inference |
|-------|----------------------------------|-------------------------------|-----------------|-----------------------------|-------------------|-----------|
| 1.    | Drug (Prochlorperazine maleate)  | White                         | 0.49            | White                       | 0.49              | No Change |
| 2.    | Pure Drug + β-Cyclodextrin       | White                         | 0.51            | White                       | 0.53              | No Change |
| 3.    | Pure Drug + HPMC                 | Light brown                   | 0.50            | White                       | 0.56              | No Change |
| 4.    | Pure Drug + Glycerol             | White                         | 0.48            | White                       | 0.49              | No Change |
| 5.    | Pure Drug + Mannitol             | White                         | 0.52            | White                       | 0.51              | No Change |
| 6.    | Pure Drug + Citric acid          | White                         | 0.54            | White                       | 0.56              | No Change |

Table 7 Evaluation data of Mouth dissolving film of prochlorperazine maleate

| Formulation | Weight variation (mg) Mean±SD | Thickness (mm) Mean±SD | Folding endurance (Times) | Drug Content (%) | Disintegration Time (sec) Mean±SD |
|-------------|--------------------------------|------------------------|---------------------------|------------------|----------------------------------|
| F1          | 48.9±0.02                       | 0.1±0.07               | 142                       | 85.1             | 36                               |
| F2          | 34.5±0.05                       | 0.08±0.04              | 126                       | 86.6             | 30                               |
| F3          | 29.8±0.04                       | 0.09±0.02              | 151                       | 97.4             | 18                               |
| F4          | 31±0.06                         | 0.07±0.08              | 124                       | 86.6             | 20                               |
| F5          | 39±0.04                         | 0.09±0.4               | 141                       | 93               | 31                               |
| F6          | 49±0.09                         | 0.1±0.09               | 130                       | 92.2             | 35                               |
| F7          | 34±0.08                         | 0.09±0.06              | 137                       | 92.3             | 36                               |
| F8          | 47.8±0.05                       | 0.08±0.07              | 145                       | 87.7             | 32                               |
| F9          | 35±0.07                         | 0.07±0.05              | 140                       | 86.4             | 35                               |

**Stability studies**

The result of stability study indicated that the drug product falls well within the proposed stability specification. The data showed that there is no significant physical or chemical change indicating that the formulation would maintain its efficacy and quality throughout its proposed shelf life.

**CONCLUSION**

In the present research work an attempt has been made to optimized, formulate and evaluate Mouth dissolving film of Prochlorperazine maleate. Prochlorperazine maleate is an antiemetic drug belongs to BCS class-ll (Low Solubility and high permeability). It has poor bioavailability and low solubility. In the present work solubility and bioavailability of drug was enhanced using inclusion complex. The inclusion complex of Drug: β-cyclodextrin was prepared in different ratio by physical mixture method. The solvent casting method was used to formulate and evaluate fast dissolving film of Prochlorperazine maleate. Addition of Drug: β-cyclodextrin inclusion complex leads to improve the dissolution characteristics and solubility of drug at optimum concentration (1:3). So, considering the above results it was found that the formulation F3 was found to be optimized formulation from the data obtained. It is observed from the formulation F3 which shown disintegration time 18 sec. and percentage cumulative drug release shown 96.39% within 180 second. Thus, it can be concluded that the drug given in the form of fast dissolving films should be advantageous for patients suffering from nausea and vomiting, providing better patient compliance and an effective mode of treatment.
REFERENCES

1. Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm 2013; 3(2):67-76.

2. Dixit, R.P. and S.P. Puthli. Oral strip technology: Overview and future potential, Journal of Controlled Release 2009; 139:94-107.

3. Indian pharmacopoeia 2010 vol-3 Government of India Ministry of Health and Family Welfare .publish by Indian Pharmacopoeia Commission 2010, 6 Edition.

4. Bhalekar R. Mangesh ., Madgulkar R. Ashwini ,Shaikh G.Shagufa ."Formulation and Evaluation of Chitosan- Based Mucoadhesive Buccal Patch of prochlorperazine MaleateAn International Journal of Pharmacy and Pharmaceutical Research, 2018; 4:61-73

5. Jain DK, Darwhekar GN, Sharma Ravi. Osmotically regulated asymmetric capsular system for sustained delivery of indomethacin. Journal of Pharmaceutical Investigation 2009; 43:27-35

6. Thangadurai S."Thin layer chromatographic separation and identification of certain phenothiazines" An Indian Journal, 2010; (3):332-336.

7. Patel AR, Dharmendra S, Jignyasha P, Raval A. Fast dissolving films (Fdfs) as newer venture in fast dissolving dosage forms. Int J Drug Deliv Res, 2010; 2:232-46.

8. Sharma Pravin K, Sharma Pankaj K, Darwhekar Gajanan N, Shrivastava Birendra, Formulation and evaluation of mouth dissolving film of tadalaBl, Journal of Drug Delivery and Therapeutics 2017; 7(7):52-55.

9. Vyass Himanshu D, Parmar Ghandhym, Shah Nirmal, Chauhan Sachin, Seth A K, Formulation and evaluation of fast dissolving film of methylcobalamin; An International Journal of Pharmaceutical Sciences; 2015; 6(4):50-68

10. Patel AR, Dharmendra S, Jignyasha P, Raval A. Fast dissolving films (Fdfs) as newer venture in fast dissolving dosage forms. Int J Drug Deliv Res, 2010; 2:232-46.

11. Nagar M. Formulation and evaluation of mouth dissolving film of antipsychotic drug aripiprazole. Der Pharmacia Lettre, 2012; (4):1221-1227